In patients with perianal Crohn’s disease (pCD) treated in routine clinical practice, the use of upadacitinib appears to have a beneficial effect on fistula outcomes, with a more pronounced effect seen for anti-TNF–naïve patients and those with shorter disease duration, according to a multicentre retrospective cohort study.